[1].参考文[2]Bland KI, Menck HR, Scott-Conner CE,et al. The National Cancer Data Base 10-1998 survey of breast carcinoma treatment at hospitals in the United States.[J].Cancer,1998,83(6):1262-1273[3]Fisher B, Montague E, Redmond C, et al.Comparison of radical mastectomy with alternative treatments for primary breast cancer[J].Cancer,1977,39:2827-[4]Fisher B, Montague E, Redmond C,et al.Ten-1985 results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation[J].N Engl J Med,1985,312:674-[5]Krag D,Weaver D,Ashikaga T,et al.The sentinel node in breast cancer a multicenter validation study.[J].N Engl J Med,1998,339(14):941-946[6]Krag DN Anderson SJ,Julian TB,et al.Technical outcomes of sentinel lymph node resection and conventional axillary lymph node dissection in patients with clinically node-nagative breast cancer results from the NSABP B-32 randomisde phase[J].Lancet Oncol,2007,8(10):881-[7]GoyalA,Newcombe RG,Chhabra A,et al.Factors affecting failed localisation and false-negative rates of sentinel node biopsy in breast cancer-results of the ALMANAC validation phase.[J].Breast Cancer Res Treat,2006,98(9):599-609[8]Bianco A, Kostarelos K, Prato M.Applications of carbon nanotubes indrug delivery[ J][J].Curr Opin ChemBiol,2005,9(6):674-[9]瞿欢,张亚男,陈卫东.纳米炭在乳腺癌前哨淋巴结示踪的实验研究[J].中国普通外科杂志,2010,19(5):489-492[10]陈江浩,杨引明,李开宗等.乳腺癌淋巴化疗与静脉化疗后腋窝淋巴结药物浓度的比较[J].癌症,2005,24(4):494-497 |